Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.

Aso E, Ferrer I.

Front Pharmacol. 2014 Mar 5;5:37. doi: 10.3389/fphar.2014.00037. eCollection 2014. Review.

2.

Alzheimer's disease; taking the edge off with cannabinoids?

Campbell VA, Gowran A.

Br J Pharmacol. 2007 Nov;152(5):655-62. Epub 2007 Sep 10. Review.

3.

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML.

J Neurosci. 2005 Feb 23;25(8):1904-13.

4.

CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.

Aso E, Ferrer I.

Front Neurosci. 2016 May 31;10:243. doi: 10.3389/fnins.2016.00243. eCollection 2016. Review.

5.

Behavioral effects of cannabinoid agents in animals.

Chaperon F, Thiébot MH.

Crit Rev Neurobiol. 1999;13(3):243-81. Review.

PMID:
10803637
6.

The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.

Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S.

J Alzheimers Dis. 2015;43(4):1115-36. doi: 10.3233/JAD-141635. Review.

PMID:
25147120
7.
8.

Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists.

Pascual AC, Martín-Moreno AM, Giusto NM, de Ceballos ML, Pasquaré SJ.

Exp Gerontol. 2014 Dec;60:92-9. doi: 10.1016/j.exger.2014.10.011. Epub 2014 Oct 18.

PMID:
25456842
9.

The influence of cannabinoids on generic traits of neurodegeneration.

Fagan SG, Campbell VA.

Br J Pharmacol. 2014 Mar;171(6):1347-60. doi: 10.1111/bph.12492. Review.

10.

Pharmacological actions of cannabinoids.

Pertwee RG.

Handb Exp Pharmacol. 2005;(168):1-51. Review.

PMID:
16596770
11.

The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.

Fride E.

Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):24-30. Review.

PMID:
15159678
12.

Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.

Harvey BS, Ohlsson KS, Mååg JL, Musgrave IF, Smid SD.

Neurotoxicology. 2012 Jan;33(1):138-46. doi: 10.1016/j.neuro.2011.12.015. Epub 2012 Jan 3.

PMID:
22233683
13.

Therapeutic potential of cannabinoids in schizophrenia.

Kucerova J, Tabiova K, Drago F, Micale V.

Recent Pat CNS Drug Discov. 2014 Apr;9(1):13-25. Review.

PMID:
24605939
14.

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J.

Brain Res. 2007 Feb 23;1134(1):162-70. Epub 2006 Dec 28.

PMID:
17196181
15.

Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Picone RP, Kendall DA.

Mol Endocrinol. 2015 Jun;29(6):801-13. doi: 10.1210/me.2015-1062. Epub 2015 Apr 13. Review.

16.

The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages.

Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J.

Brain Res. 2009 Aug 4;1283:148-54. doi: 10.1016/j.brainres.2009.05.098. Epub 2009 Jun 6.

PMID:
19505450
17.

Differential roles of CB1 and CB2 cannabinoid receptors in mast cells.

Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H.

J Immunol. 2003 May 15;170(10):4953-62.

18.

The multiplicity of action of cannabinoids: implications for treating neurodegeneration.

Gowran A, Noonan J, Campbell VA.

CNS Neurosci Ther. 2011 Dec;17(6):637-44. doi: 10.1111/j.1755-5949.2010.00195.x. Epub 2010 Sep 28. Review.

PMID:
20875047
19.

Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy.

Vera G, Cabezos PA, Martín MI, Abalo R.

Pharmacol Biochem Behav. 2013 Apr;105:205-12. doi: 10.1016/j.pbb.2013.02.008. Epub 2013 Feb 27.

PMID:
23454533
20.

Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.

Ribeiro R, Yu F, Wen J, Vana A, Zhang Y.

Neuroscience. 2013 Dec 19;254:427-42. doi: 10.1016/j.neuroscience.2013.09.005. Epub 2013 Sep 11.

PMID:
24036373

Supplemental Content

Support Center